Ji Yao Holding Group Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Ji Yao Holding Group has been growing earnings at an average annual rate of 34.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 23.5% per year.
Belangrijke informatie
34.8%
Groei van de winst
34.9%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | -23.5% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -120.3% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Ji Yao Holding Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 363 | -436 | 244 | 12 |
| 30 Jun 24 | 354 | -397 | 223 | 13 |
| 31 Mar 24 | 350 | -370 | 215 | 13 |
| 31 Dec 23 | 346 | -349 | 212 | 13 |
| 30 Sep 23 | 348 | -112 | 160 | 14 |
| 30 Jun 23 | 396 | -124 | 183 | 16 |
| 31 Mar 23 | 443 | -244 | 253 | 17 |
| 01 Jan 23 | 489 | -276 | 259 | 18 |
| 30 Sep 22 | 562 | -453 | 285 | 15 |
| 30 Jun 22 | 588 | -460 | 268 | 14 |
| 31 Mar 22 | 638 | -469 | 329 | 17 |
| 01 Jan 22 | 685 | -451 | 341 | 17 |
| 30 Sep 21 | 628 | -488 | 378 | 17 |
| 30 Jun 21 | 673 | -528 | 466 | 18 |
| 31 Mar 21 | 673 | -374 | 334 | 16 |
| 31 Dec 20 | 649 | -380 | 336 | 16 |
| 30 Sep 20 | 732 | -1,983 | 736 | 92 |
| 30 Jun 20 | 813 | -1,880 | 651 | 89 |
| 31 Mar 20 | 907 | -1,841 | 669 | 91 |
| 31 Dec 19 | 1,066 | -1,772 | 655 | 92 |
| 30 Sep 19 | 1,196 | 127 | 256 | 17 |
| 30 Jun 19 | 1,114 | 162 | 214 | 19 |
| 31 Mar 19 | 1,105 | 210 | 175 | 17 |
| 31 Dec 18 | 942 | 217 | 155 | 15 |
| 30 Sep 18 | 776 | 203 | 84 | 11 |
| 30 Jun 18 | 771 | 203 | 85 | 16 |
| 31 Mar 18 | 707 | 205 | 77 | 12 |
| 31 Dec 17 | 700 | 202 | 79 | 10 |
| 30 Sep 17 | 750 | 180 | 101 | 7 |
| 30 Jun 17 | 767 | 200 | 96 | 0 |
| 31 Mar 17 | 736 | 189 | 87 | 0 |
| 31 Dec 16 | 747 | 186 | 83 | 0 |
| 30 Sep 16 | 666 | 119 | 71 | 0 |
| 30 Jun 16 | 632 | 115 | 69 | 0 |
| 31 Mar 16 | 655 | 132 | 71 | 0 |
| 31 Dec 15 | 678 | 136 | 72 | 0 |
| 30 Sep 15 | 703 | 146 | 66 | 0 |
| 30 Jun 15 | 616 | 119 | 64 | 0 |
| 31 Mar 15 | 467 | 85 | 57 | 0 |
| 31 Dec 14 | 343 | 57 | 51 | 0 |
| 30 Sep 14 | 223 | 40 | 37 | 0 |
| 30 Jun 14 | 174 | 29 | 35 | 0 |
| 31 Mar 14 | 176 | 28 | 35 | 0 |
| 31 Dec 13 | 165 | 27 | 32 | 0 |
Kwaliteitswinsten: 300108 is currently unprofitable.
Groeiende winstmarge: 300108 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 300108 is unprofitable, but has reduced losses over the past 5 years at a rate of 34.8% per year.
Versnelling van de groei: Unable to compare 300108's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 300108 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 300108's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.